Hepatobiliary/Pancreas Pathology: SY11-3 PANCREATIC DUCTAL ADENOCARCINOMA: NEOADJUVANT THERAPIES AND PATHOLOGY.

Journal Article

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal human malignancies with less than 5% five-year survival rate. Despite significant improvements in medical and surgical oncology and postoperative mortality rate, the overall survival for patients with pancreatic cancer has not changed significantly in the last four decades. Neoadjuvant chemoradiation therapy (NCT) is increasingly used to treat patients with potentially resectable PDAC, especially for patients with borderline resectable disease. However, analysis of prognostic factors is limited for patients with PDAC treated with NCT and pancreaticoduodenectomy. We systemically examined the pancreaticoduodenectomy specimens from 240 consecutive patients with PDAC who received NCT and pancreaticoduodenectomy between 1999 and 2007 at our institution. We found that posttreatment pathologic stage, pathologic tumor response grading, tumor involvement of the superior mesenteric/portal vein, tumor invasion into the muscular vessels, and perineural invasion are significant prognostic factors in our patient population. Therefore careful pathologic evaluation of the pancreatectomy specimens plays a key role in predicting prognosis of patients with PDAC who received NCT and pancreaticoduodenectomy.

Full Text

Duke Authors

Cited Authors

  • Wang, H; Estrella, JS; Chatterjee, D; Katz, MH; Rashid, A; Wang, H; Wolff, RA; Varadhachary, GR; Lee, JE; Pisters, PW; Abbruzzese, JL; Fleming, JB

Published Date

  • October 2014

Published In

Volume / Issue

  • 46 Suppl 2 /

Start / End Page

  • S25 -

PubMed ID

  • 25188109

Electronic International Standard Serial Number (EISSN)

  • 1465-3931

International Standard Serial Number (ISSN)

  • 0031-3025

Digital Object Identifier (DOI)

  • 10.1097/01.pat.0000454135.19954.47

Language

  • eng